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INTRODUCTION
The most common diagnosed noncutaneous neoplasm in males is prostate cancer. [1] In term of new cases, it is the sixth most common cancer in the world. [2] In India, it is the second most leading site of cancer among males in large cities and epidemiology also showing rapidly increasing trends in all region of India in all population-based cancer registries. [3, 4] The clinicopathological factor such as Gleason score, tumor stage along with prostate-specific antigen (PSA) level is taken as diagnostic and prognostic factors, these however fails to predict accurate clinical outcome in individual cases. [5, 6] Zinc inhibits nuclear factor-kappa B pathways, antiproliferative and induces apoptosis in abnormal cells. [7, 8] The P13k/Akt signaling cascade works with the transforming growth factor-beta/SMAD signaling cascade to ensure prostate cancer cell survival and protection against apoptosis. [9] Macrophage inhibitory cytokine-1 stimulates the focal adhesion kinase signaling pathway which leads to prostate cancer cell growth and survival. [10] Prostate-specific membrane antigen stimulates the development of prostate cancer by increasing foliate level for the cancer cells to use to survive and growth. [11] Invasion and metastasis of tumor cell provoked by protein that stimulates its attachment to host cellular or extracellular matrix, proteolysis of host barriers to invasion, its locomotion, and colony formation in the organ focused for metastasis. [12, 13] Nonmetastatic nm23 gene plays a critical role to regulate dissemination of tumor cell at molecular level by their ability to inhibit the formation of metastasis while not affecting the growth of primary in vitro. [14, 15] The first metastasis suppressor gene, nm23, was identified in 1988, and since then, eight suppressor genes have been confirmed. [16, 17] Strong expression of nm23H1 likely represents an early event with or without metastases and to evaluate its role as a predictor in the metastases of prostatic carcinoma.
Clinical evaluation
The mean age of the patients with adenocarcinoma was 66.90 ± 6.89 years, whereas the same of the patients with BPH was 63.60 ± 7.72 years. On comparing the data statistically, no significant difference was observed between two groups (P = 0.935) [ Figure 1 ]. All the 10 (100%) cases of BPH had PSA levels ≤10 ng/ml. None of cases of BPH had PSA levels between 11 and 20 ng/ml. However, 6 (30%) of adenocarcinoma cases had PSA levels between 11 and 20 ng/ml and remaining 13 (65%) of adenocarcinoma cases had PSA levels above 20 ng/ml. Statistically, the difference in PSA levels of two diagnoses was significant (P < 0.001) [ Figure 2 ].
Morphological evaluation
Out of 30 cases enrolled for the study, there were 20 cases of prostate adenocarcinoma (66.7%) and 10 cases were of BPH (33.3%). Out of the 20 cases of adenocarcinoma prostate, a total of 4 (20%) cases had metastatic activity. Remaining 16 (80%) cases did not have a metastatic activity.
The Gleason scores ranged from 5 to 8. Mean Gleason score among patients of adenocarcinoma was 6.55 ± 0.95. There were 55% patients having Gleason score ≥7. Out of 4 cases with metastasis, 3 (75%) had Gleason scores ≥7.
Majority (80%) patients were Stage II adenocarcinoma and only 4 (20%) were Stage IV adenocarcinoma. Out of 4 cases with metastasis, 1 (25%) was diagnosed by biopsy while the remaining 3 (75%) were diagnosed by bone scintigraphy.
Immunohistochemical evaluation
IHC expression for nm23H1 gene showed positive findings in all the cases in adenocarcinoma and BPH groups (P = 1) [ Figure 3 ].
Comparison of mean % expression of gene nm23H1 in patients of adenocarcinoma without metastasis, patients of adenocarcinoma with metastasis, and those with BPH revealed the values were similar. Statistically, there was no significant difference among different diagnostic entities (P = 0.173) [ Table 1 ]. in the development of carcinoma of the prostate. Both protein, nm23H1, and nm23H2 are localized to the cytoplasm, nucleus, and cell membrane. [18] Tumor grade, clinical stage, and serum PSA have become the cornerstone variables in determining treatment options for patients with prostatic carcinoma. Therefore, the present study comprised of clinicopathological correlation of various markers including tumor stage, PSA level, and expression of nm23H1 in prostatic lesions.
Aims and objectives 1. To correlate nm23H1 with presence of metastases, tumor stage, tumor grade, and PSA levels 2. To study the expression of nm23H1 in prostate cancer versus benign hyperplasia of prostate.
MATERIALS AND METHODS
The present study includes selected thirty biopsy-proven cases of benign prostate hyperplasia (BPH) and prostatic carcinoma obtained from needle biopsy, transurethral resections, and total prostatectomy in the period of 1 year at tertiary level hospitals. All the samples were processed for histopathology, stained with hematoxilin and eosin. Sectioned was reviewed for tumor, node, and metastasis (TNM) staging, grading by Gleason system.
Immunohistochemistry (IHC) for the expression of nm 23H1 was performed in unstained paraffin-embedded tissue section using primary antibody nm23H1 mouse monoclonal antibody and secondary antibody mACH universal HRP-polymer kit. Slides were coated with 3-aminopropyl triethoxysilane. Sectiones were deparaffinized and incubated for 30 min in 0.3% hydrogen peroxide in methanol, rinsed with tris-buffered. Antigen retrieval was performed followed by cooling and washing steps in tris-buffer at pH 7.5. Tissue specimen were treated overnight with primary antibody at 4°C followed by 1 h incubation at room temperature and then incubated with secondary antibody. Diluted diaminobenzidine tetrahydrochloride was used to develop color. The preparation was counter stained with hematoxylin. The estimated proportion of intense staining cells was determined in five fields at ×400 and graded as 0 (0%-25%), +1 (26%-50%), +2 (51%-75%), and +3 (76%-100%).
Preoperative serum PSA was performed in all cases (>20 ng/ml were considered as raised PSA level).
Statistical analysis
The statistical analysis was done using SPSS version 15.0 Statistical Analysis Software. Manufactured by IBM, Chicago, Illinois, USA.The values were represented in number (%) and mean ± standard deviation. Level of significance was expressed as "P".
RESULTS
The present study was carried out to study the expression of nm23H1 gene among cases of adenocarcinoma of the prostate Although as compared to those having Gleason score of lower order (<7), the mean % expression was higher among those having Gleason score of higher order (≥7), the difference was not significant statistically (P < 0.180). No significant association between TNM stage and % mean IHC expression was observed (P > 0.05) [ Table 2 ].
In all the cases, the grade of expression was 3+. There was no difference in grade of expression in different groups (P = 1); majority of cases in all the groups had strong intensity of expression. Diffuse type was more common in adenocarcinoma with and without metastasis as compared to cases of BPH. However, the association was not significant statistically (P = 0.475) [ Table 3 and Figures 4a, b, 5a , b, 6a-c].
PSA values >20 ng/ml showed maximum % mean expression (98.64%) as compared to PSA levels <10 ng/ml (96.91%); however, the association was statistically nonsignificant (P > 0.05) [ Table 4 ].
Receiver operator curve analysis shows that the area under a curve was 0.707. The cutoff ≥96.90% indicates a sensitivity of 100% and a specificity of 46.2%.
DISCUSSION
The pathogenesis of metastasis consists of linked, sequential, and selective steps that are regulated by transient or permanent changes in different genes. nm23H1/nucleoside-diphosphate kinase is associated with tumor metastasis. Its expression is divergent in various malignant tumors. The mechanism by which nm23H1 exerts its metastasis suppressor functions involves multiple pathway, which remains to be clarified. [19] Yang et al. in their study found inverse correlation of nm23H1 with lymph node metastasis and negative correlation between the expression of nm23H1, VEGF-C mRNA, and microlymphatic count. [20] Lapek et al. in their study discussed the evidence of histamine and aspartic acid phosphorylation in prostate cancer and the potential function of nm23H1 in suppressing the metastasis. [21] In prostate cancer, an inverse relationship between nm23H1 expression and metastatic was described, but a correlation with the progression of primary tumors is controversially discussed. [22, 23] Prowatke et al. found no correlation with clinicopathological parameters of primary prostate carcinoma. [24] Ding et al. observed positive expression of nm23H1 mRNA in prostate cancer and negative correlation between the nm23H1 expression and metastasis. [25, 26] Sethi and Kang and Yadav et al. in their study found that all the metastatic suppressor genes do not influence metastatic potential in similar ways. [27, 28] Lombardi et al. stated that the nm23H1 gene and its protein are expressed physiologically during cell growth and differentiation and that this expression varies in tissues. [29] In our study, there is no significant difference among all three groups of BPH, adenocarcinoma of the prostate, and adenocarcinoma of the prostate with metastasis in mean percentages of IHC expression, IHC grading, IHC intensity, and diffuse or focal positivity. Our study is in accordance with Igawa et al. stated that in the prostate, nm23H1 does not behave as a metastases suppressor gene, and in the contrary, this is more correlated to metastases. [30] Kandil et al. in their study found that in the prostate, nm23H1 does not behave as metastatic suppressor gene, and in the contrary, it is more correlated to metastasis. [31] In our study, mean IHC expression was 96.29% in Stage II and 94.50% in Stage IV cases of prostatic carcinoma. Our study shows no significant association between tumor stage and percentage mean of IHC expression. In the present study, higher and lower Gleason grade scores both show almost strong and >94.0% IHC expression and were not statistically significant. However, Stravodimos and Constantinides and Ding et al. concluded that there was negative correlation between nm23H1 staining, tumor stage, and Gleason score. [32] In the present study, mean PSA levels of patients of adenocarcinoma with and without metastasis were 53.47 ± 98.98 ng/ml as against 5.48 ± 2.72 ng/ml among patients of BPH and were statistically significant (P ≤ 0.001). Hence, our study is consistent with higher level of PSA and adenocarcinoma of the prostate with and without metastasis. [33] PSA levels are grouped in the <10, 11-20, and >20 ng/ml showing mean percentage of nm23H1 expression 96.91, 97.35, and 98.64, respectively (P > 0.05). Cherry et al. also found large fluctuation of the serum PSA level. Hence, increased level can be found in patients with either localized or metastatic cancer. [34] However, the recent research suggests that the rate of increase of PSA (the PSA velocity) is not a specific marker for prostate cancer. [35] Majority of patients of BPH and adenocarcinoma with or without metastasis belong to the age range of 61-70 years. No significant difference was observed between two groups.
Metastasis is most common cause of mortality in cancer patients.
In the present scenario, further study for targeted molecular therapeutics aimed at tumor cells is required for treating as well preventing metastasis. [36] Gossypol could have the antimetastatic chemotherapeutic benefit for prostate cancer. It plays a role in metastases suppression, and its mechanism of action in this cell line model may involve downregulation of Bcl-2 and Bcl-xL protein and upregulation of nm23H1 protein. [37, 38] 
CONCLUSION
The receiver operating characteristic curve shows nm23H1 expression cannot be used as an effective tool to differentiate among the cases of BPH and adenocarcinoma of the prostate with or without metastases. The present study stated that nm23H1 gene does not behave as metastatic suppressor gene in prostate carcinoma. Hence, the search for other markers of antimetastatic potential in prostate carcinoma should be continued. Various other factors inherent to host and malignancy can be associated with the mechanism that suppresses the metastatic process in this disease. 
